Japan, US And 5EU Psoriasis Drugs Market Analysis And Forecasts To 2024

MarketStudyReport.com adds “Psoriasis –Japan, US and 5EU Drug Forecast and Market Analysis to 2024” new report to its research database. The report spread across 210 pages with table and figures in it.

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies-interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor-Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs-especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developments of biosimilars are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

Psoriasis -Japan Drug Forecast and Market Analysis to 2024
Japan has not approved Amgen?s Enbrel for the treatment of psoriasis, and we expect this to remain so. However, Humira, Stelara, and more recently, Cosentyx are strong choices as branded drugs in Japan. Humira and Stelara are both expected to go off-patent in 2017 and 2021, respectively, while Cosentyx is expected to remain patented well past the forecast period end. Get Sample Copy @ http://www.marketstudyreport.com/request-a-sample/?search=psoriasis-japan-drug-forecast-and-market-analysis-to-2024/.

Psoriasis -US Drug Forecast and Market Analysis to 2024
The US is the largest psoriasis market, although it does not have the highest diagnosed prevalence rates of psoriasis. The US will experience major brand erosion beginning with Humira in 2016, followed by Remicade in 2018 and Stelara in 2023; Enbrel is protected until 2028. Biosimilars are likely to launch in 2016 for adalimumab and will take some patient share away from Humira. Although biosimilar uptake will be favored for its cost effectiveness, unclear requirements for demonstrating interchangeability with originator biologics, as well as strong preferences for originator products among dermatologists, could be hindering factors. Get a Sample Copy @ http://www.marketstudyreport.com/request-a-sample/?search=psoriasis-us-drug-forecast-and-market-analysis-to-2024/

Psoriasis -5EU Drug Forecast and Market Analysis to 2024
The 5EU contributed 31.6% of the global market'share in the psoriasis market in 2014. Similarly to the US, the drug classes spanning the 5EU psoriasis market were: TNF inhibitors, an IL-12/IL-23 inhibitor, IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, a PDE-4 inhibitor, systemic therapies, biosimilars, and topical therapies. Get a Sample Copy @ http://www.marketstudyreport.com/request-a-sample/?search=psoriasis-5eu-drug-forecast-and-market-analysis-to-2024/

Scope

• Overview of Psoriasis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in the US, Japan and 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in the US, Japan and 5EU from 2014-2024.
• Analysis of the impact of key events as well the drivers and restraints affecting the US, Japan and 5EU Psoriasis market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2014-2024 in US, Japan and 5EU.

About Market Study Report
Market Study Report offers research reports on global or regional markets, competitive information, emerging markets and trends then Market Study Report is the platform that can help you in achieving any of these objectives. Our 24/7 customer support helps clients find the best solution and find best prices for research reports. We help clients with customization of any report at low costs.